Literature DB >> 17602742

Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, i.e., storage phosphor autoradiography, RT-PCR and immunohistochemistry.

W P ter Beek1, I Biemond, E S M Muller, M van den Berg, C B H W Lamers.   

Abstract

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation accompanied by changes in motility. It is known that regulatory peptides like substance P (SP) are important pro-inflammatory peptides which are also involved in neuronal conduction. To get clues for new diagnostic and therapeutic approaches we describe the SP receptor (NK-1) distribution in IBD compared to control intestinal tissue, on mRNA and protein level by three complementary techniques. Autoradiography showed differences within the intestinal wall of control patients; mucosal binding was 17 fmol/g and muscular binding was significantly (p=0.01) higher (98 fmol/g). In inflamed specimens of patients with IBD mucosal SP binding was increased compared to controls (55+/-10 vs 18+/-4 fmol/g mucosa, p=0.002). However RT-PCR showed that the mRNA content of the NK-1 receptor in these samples was not increased. In non-inflamed samples of patients with Crohn's disease (CD) and ulcerative colitis (UC) SP binding was similar as in controls, while mRNA was significantly decreased in CD patients (0.7+/-0.02 vs 4.4+/-0.7, p=0.01) but not in UC patients (4.4+/-0.7 vs 4.1+/-1.4). Immunohistochemistry identified a broad spectrum of NK-1 receptor locations in control intestine. No aberrant expression in IBD was found. This study showed that although there was no difference in location of the SP receptors in IBD patients versus controls, the quantity of SP binding was significantly increased in the inflamed mucosa of IBD patients, while the mRNA level was not increased. Further a difference in mRNA level between non-inflamed tissue of CD and UC patients was shown, with mRNA in CD being lower. These changes in SP receptor expression during chronic inflammation suggest that SP receptors are a potential target for therapeutic regulation of the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602742     DOI: 10.1016/j.npep.2007.05.002

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  11 in total

1.  Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors.

Authors:  Luca Antonioli; Carolina Pellegrini; Matteo Fornai; Erika Tirotta; Daniela Gentile; Laura Benvenuti; Maria Cecilia Giron; Valentina Caputi; Ilaria Marsilio; Genny Orso; Nunzia Bernardini; Cristina Segnani; Chiara Ippolito; Balázs Csóka; Zoltán H Németh; György Haskó; Carmelo Scarpignato; Corrado Blandizzi; Rocchina Colucci
Journal:  Purinergic Signal       Date:  2017-08-14       Impact factor: 3.765

2.  Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.

Authors:  Raymond A Isidro; Myrella L Cruz; Angel A Isidro; Axel Baez; Axel Arroyo; William A González-Marqués; Carmen González-Keelan; Esther A Torres; Caroline B Appleyard
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

3.  Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.

Authors:  Earl Gillespie; Susan E Leeman; Luisa A Watts; Jennifer A Coukos; Michael J O'Brien; Sandra R Cerda; Francis A Farraye; Arthur F Stucchi; James M Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

4.  MicroRNAs may mediate the down-regulation of neurokinin-1 receptor in chronic bladder pain syndrome.

Authors:  Veronica Sanchez Freire; Fiona C Burkhard; Thomas M Kessler; Annette Kuhn; Annette Draeger; Katia Monastyrskaya
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

5.  Secretion of immunomodulating neuropeptides (VIP, SP) and nitric oxide synthase in porcine small intestine during postnatal development.

Authors:  A Kovsca Janjatovic; H Valpotic; D Kezic; G Lacković; G Gregorovic; S Sladoljev; G Mršić; M Popovic; I Valpotic
Journal:  Eur J Histochem       Date:  2012-09-13       Impact factor: 3.188

Review 6.  Neuroinflammation in inflammatory bowel disease.

Authors:  Shaheen E Lakhan; Annette Kirchgessner
Journal:  J Neuroinflammation       Date:  2010-07-08       Impact factor: 8.322

7.  Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis.

Authors:  Zeynep Gök Sargın; Nuray Erin; Gokhan Tazegul; Gülsüm Özlem Elpek; Bülent Yıldırım
Journal:  PLoS One       Date:  2017-12-12       Impact factor: 3.240

8.  Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity.

Authors:  Luca Antonioli; Valentina Caputi; Matteo Fornai; Carolina Pellegrini; Daniela Gentile; Maria Cecilia Giron; Genny Orso; Nunzia Bernardini; Cristina Segnani; Chiara Ippolito; Balázs Csóka; György Haskó; Zoltán H Németh; Carmelo Scarpignato; Corrado Blandizzi; Rocchina Colucci
Journal:  Int J Obes (Lond)       Date:  2018-08-06       Impact factor: 5.095

9.  Basal Plasma Levels of Copeptin are Elevated in Inactive Inflammatory Bowel Disease after Bowel Resection.

Authors:  Bodil Ohlsson; Olle Melander
Journal:  Drug Target Insights       Date:  2015-07-13

10.  Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.

Authors:  Carolina Pellegrini; Matteo Fornai; Rocchina Colucci; Erika Tirotta; Fabio Blandini; Giovanna Levandis; Silvia Cerri; Cristina Segnani; Chiara Ippolito; Nunzia Bernardini; Karolina Cseri; Corrado Blandizzi; György Haskó; Luca Antonioli
Journal:  J Neuroinflammation       Date:  2016-06-13       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.